Understanding how ARID1A mutations affect ovarian cancer metabolism
Characterize the metabolic landscape of ARID1A-mutated ovarian cancer
This study is looking at how certain changes in ovarian clear cell carcinoma cells, specifically those with a mutation in the ARID1A gene, affect their energy production, with the goal of finding new treatment options that could help patients with this type of cancer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11031554 on NIH RePORTER |
What this research studies
This research investigates the metabolic characteristics of ovarian clear cell carcinoma (OCCC) that have mutations in the ARID1A gene. By focusing on the mitochondrial respiration processes in these cancer cells, the study aims to identify specific components of the mitochondrial Electron Transport Chain (mETC) that are crucial for the survival of ARID1A-deficient tumors. The researchers will conduct genetic screenings and proteomic analyses to uncover potential therapeutic targets that could lead to more effective treatments for patients with this type of cancer. This approach is innovative as it seeks to provide insights into the unique vulnerabilities of ARID1A-mutated tumors, which may differ from other cancer types.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with ovarian clear cell carcinoma who have ARID1A mutations.
Not a fit: Patients with ovarian cancer who do not have ARID1A mutations may not benefit from the findings of this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for patients with ARID1A-mutated ovarian cancer, improving treatment outcomes and survival rates.
How similar studies have performed: While targeting mitochondrial respiration in cancer is a growing area of interest, this specific approach focusing on ARID1A mutations is relatively novel and has not been extensively tested.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Bazzaro, Martina — University of Minnesota
- Study coordinator: Bazzaro, Martina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.